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The current state of 
homeopathic research 
 
 
This report on the current state of homeopathic research provides a summary on the research areas 
of healthcare research, randomised controlled clinical trials, meta-analyses and basic research. 
 
It aims to contribute to the discussion within the field of homeopathy concerning the need for research, 
the relevance of individual research fields and methods, and their role in future research strategies. 
 
We are also publishing this report on the current status of scientific research, moreover, for the benefit 
of medical science as a whole and the public. 
 
Whilst the conventional development of medicinal products is based on research which must then 
stand up to medical practice, homeopathy is primarily a successful medical practice that must stand up 
to scientific research. 
 
Outcome studies investigating homeopathic treatment under routine conditions have reported 
clinically relevant improvements in symptoms and quality of life, often comparable with those under 
conventional treatments, but with fewer adverse effects. In half of all health economic evaluations 
homeopathic treatment showed less costs. Methodologically, a causal relationship between drug 
therapy and therapeutic outcome cannot be deduced from those studies. 
 
The randomised controlled clinical trials investigated here, studies with good methodology into 
individualised homeopathy with high potencies only, have indicated, like earlier studies, that classical 
homeopathy is superior to placebo, and that remedies in high potencies have a specific effect. A 
definitive scientific statement cannot be made at present given the heterogeneous nature of the data 
and the small number of studies of good quality. 
 
A review of the meta-analyses of homeopathy reveals results which mostly are statistically significant 
compared to placebo, suggesting specific efficacy from potentised remedies. Depending on the 
selection criteria applied, different studies are thereby included in the analysis. The majority of the 
studies reported in all the examined reviews (also Shang et al.), including those with good 
methodology, suggest that homeopathic treatment is superior to placebo. These findings are in part 
markedly qualified by the authors of the respective meta-analyses in their (comment/discussion and) 
conclusion. The stated caveats, e.g. with respect to study quality, thereby do not always reflect the 
usual scientific standards, or they actually refer explicitly to the postulated implausibility of the efficacy 
of high-potency medicines. 
 
There are a number of high-quality basic research studies that report specific effects also for high 
potencies, inclusive also of independently replicated experimental models. There are initial empirical 
results pointing to the physicochemical and pharmaceutical, as well as biological ways homeopathic 
remedies work, but no theory is fully developed yet. 
 
A summary analysis of the clinical research data offers sufficient evidence of the therapeutic 
effectiveness of homeopathic treatment. 
 
The results from numerous placebo-controlled trials and basic research experiments suggest, 
moreover, that potentised medicines offer a specific efficacy. 
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Put in perspective, there are many important open research areas – notably: 
• Basic research into the optimisation of laboratory models and the understanding of the mode 
of action 
• Independent replications of studies in clinical and basic research 
• Exploration of the provision of homeopathic care in reality, also combined with conventional 
medicine 
• Health economic analyses to evaluate the costs and benefits (cost effectiveness) 
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Clinical outcome research in homeopathy 
 
Michael Teut 
 
_________________________________________________________________________________ 
 
 
Background 
 
Although randomised clinical trials (RCTs) are regarded as the “gold standard” in clinical research, 
they do have drawbacks: As a rule, they are conducted at selected research centres by selected 
physicians, with a selection of patients who in most cases have been enlisted. 
 
Often, however, routine practice reveals many years later that the medicinal products are given to 
other patients in another context and with different concomitant conditions and medications to those in 
the registration trials, resulting in different outcomes and sometimes surprising adverse effects. The 
results from RCTs thus can only be generalized to the clinical routine to a limited degree. 
 
For this reason, additional clinical studies that examine the effectiveness and safety of medicines 
under everyday routine care condtions and with everyday patients are important and increasingly 
demanded by health authorities. Such clinical studies, which are performed in everyday settings, are 
referred to as “clinical outcome research”. 
 
In outcome studies homeopathy is usually studied as an integrated and complex therapeutic concept 
(e.g. consisting of a specific consultation, examination and medication). Prospective observational or 
cohort studies (without control group) describe medical care as it actually takes place in clinical reality. 
However, uncontrolled studies do not permit to assess about the efficacy of a specific intervention as 
the result may be influenced by other factors (e.g. the patients social status, income, lifestyle or other, 
concurrent therapies). 
 
Prospective observational or cohort studies including a control group (e.g. homeopathy versus 
conventional treatment) permit to compare therapeutic alternatives in the routine care settings. 
However, the outcomes may be influenced by other relevant features or characteristics than the 
interventions in different patient groups (e.g. a more healthy lifestyle of the group undergoing 
homeopathic treatment, a different social, economic or educational status). 
 
It is possible to statistically adjust for differences in the patient groups to a certain extent. If optimal 
comparability is desired, however, it is better to make use of randomisation technique: If patients are 
randomly assigned to treatment groups that reflect the routine setting (randomised, pragmatic study), 
efficacy can be judged most reliably. 
 
Also health economic questions can be answered by outcome research. A cost analysis addresses 
only the costs of treatment, but not the outcome. A cost-cost analysis compares the costs of two 
alternative treatments – again, without taking into account benefits of the treatment. A cost-benefit 
analysis examines the benefit in monetary units; a cost-effectiveness analysis examines costs related 
to natural parameters (e.g. years of life gained). A cost-utility analysis examines costs in relation to 
benefits, reported as utility value, mostly in “quality-adjusted life years” (QALYs). 
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Results 
 
To date homeopathic outcome research has focussed largely on therapy administered by physicians. 
Most of the available clinical studies were performed in Europe and India. 
 
The largest homeopathic cohort study to be conducted so far in German speaking countries included 
3981 patients in the clinics of more than 100 homeopathic physicians in Germany and Switzerland 
over a period of eight years (1, 2). The most common indications for homeopathic treatment were 
long-term, chronic diseases: headaches and migraines in women; allergic rhinitis and hypertension in 
men; atopic eczema and recurrent infections in children. The pre-/post-treatment-comparisons of 
outcomes showed a reduction in the intensity of symptoms on average by almost 50%, and a marked 
improvement in quality of life. The intensity of the symptoms was evaluated by the physicians and 
patients on symptom scales (Numeric Rating Scale); quality of life was assessed using the SF-36 
questionnaire. The decrease in symptoms was greatest within the first three months of treatment. The 
noted improvements in the symptoms and quality of life were long-lasting. In follow-up questionnaires 
the patients still reported lasting improvements eight years after starting treatment (2). Clinically 
relevant improvements were seen in this study for groups with the following diagnoses: Migraine and 
headache (3, 4), chronic rhinitis (5), back pain (6), geriatric patients (7), menstrual pain (8) and 
psoriasis (9). As this study was designed without a control group, the question arises whether the 
improvements reflect a therapeutic effect or the spontaneous course of the disease conditions. In this 
regard the term “regression toward the mean” is used to describe the shift of extreme values (e.g. 
when a disease is active) over time towards the mean value. A statistical analysis of the quality of life 
data from this large cohort study did not suggest a sole “regression toward the mean” effect (10). 
 
An earlier prospective comparative observational study in the 1990s (11) already compared outcomes 
of patients on homeopathic treatment to those on conventional treatment in routine care. 465 patients 
with diseases of the upper or lower respiratory tracts and ears (including allergies) were included, 281 
received homeopathic and 175 conventional treatment. After 14 days, 82.6% of the patients on 
homeopathic and 68% of those on conventional treatment were free of symptoms or greatly improved; 
67.3% of the patients on homeopathic and 56.6% of the patients on conventional treatment improved 
within three days. Adverse effects occurred in 22.3% of the patients on conventional treatment, but 
only in 7.8% of the patients on homeopathic treatment. In 2007, the authors published the data from 
an even larger multinational prospective obeservational study including 1577 patients with acute 
respiratory and ear disorders: 857 patients received homeopathic treatment, and 720 patients 
conventional therapy. The improvements were similar in both groups after seven days, but recovery 
was more rapid in the homeopathic group (12). 
 
In another comparative, prospective observational study (13), the outcomes of patients insured by a 
German health insurance fund receiving homeopathic treatment were compared to those on 
conventional medicine alone. A total of 459 patients took part. There was a more marked reduction of 
symptom severity (recorded by patients and physicians) in the homeopathy group compared to the 
conventional treatment group; in addition the costs were lower under homeopathic treatment. 
 
In another prospective observational study including 1097 Norwegian patients given homeopathic 
treatment seven out of ten patients reported a clear and clinically relevant symptoms reduction during 
a six-month course of homeopathic treatment (14). 
 
A prospective observational study conducted at a British hospital outpatient department in a 
population of 6544 patients revealed a clinical improvement in 70.7% of those under homeopathic 
treatment, and a good or very good therapeutic outcome in half of all patients (15). 
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A prospective observational study at an Italian hospital also reported at least a moderate clinical 
improvement in 74% of all included patients (16). 
 
An observational study in 772 children conducted in six European countries and Brazil (17) reported a 
high level of treatment satisfaction and an increase in quality of life after two months of homeopathic 
treatment; adverse effects were observed in only 4.2% of the children. 
 
Several observational studies are also available for diagnosis-related groups of patients: 
•  Comparative prospective observational studies into the routine treatment of children with atopic 
eczema have been conducted in Germany (18, 19, 20). Similarly good outcomes from both 
homeopathic and conventional treatment in terms of the skin and quality of life were reported, 
although homeopathic treatment was more expensive. 
•  A comparative, prospective observational study in cancer patients with different diagnoses in 
Germany compared conventional  treatment plus homeopathy (259 patients) against 
conventional therapy alone (380 patients) (21). Quality of life was found to be better in the group 
receiving homeopathic treatment. Further studies in oncology revealed a high level of treatment 
satisfaction in the case of complementary homeopathic treatment (22) and a decrease in 
symptoms of oestrogen withdrawal in female patients with breast cancer under complementary 
homeopathic treatment (23). In a recent randomised pragmatic trial in Austria cancer patients 
were randomly assigned to receive either conventional therapy or conventional therapy plus 
homeopathic treatment (24). For the combination group a significantly better quality of life and far 
greater well-being was reported. 
•  A small comparative prospective observational study in patients with diabetic neuropathy 
revealed an improvement in clinical symptoms of patients on homeopathic treatment (n=45) 
compared to those on conventional therapy (n=32) (25). A prospective observational study in 
India including 336 patients likewise demonstrated a clinical improvement of neuropathy under 
homeopathic treatment within 12 months (26). 
•  The French EPI3-MSD cohort study reported that patients with musculoskeletal symptoms 
receiving homeopathic treatment from their general practitioner had similar outcomes to patients 
on conventional treatment, but that approx. 50% fewer were taking nonsteroidal antirheumatic 
drugs (27). 
•  Clinically relevant improvements were reported by other homeopathic prospective observational 
studies, amongst others, headaches (28, 29, 4), otitis media (30), male infertility (31), acne (32), 
chronic sinusitis (33,5), Chickungunya disease (34), menopausal symptoms (35), asthma (36), 
allergies (37) and injuries (38). 
 
Health economic studies investigating homeopathy naturally reflect the costs within the national 
healthcare system. A systematic review performed in 2014 (39) summarises the results from 14 health 
economic analyses of homeopathy covering more than 3500 patients; ten studies included a control 
group. In eight out of 14 studies improvements in health and cost savings were reported; in four 
studies the outcomes corresponded to those of the conventional control, with equivalent costs. 
 
Two studies found that the outcomes were comparable to conventional therapy, albeit with higher 
costs. One of the first studies into the costs of medical homeopathy under the integrated care 
contracts (Integrierte Versorgung) of the statutory health insurance funds in Germany revealed that 
the costs of additional homeopathic treatment were higher than those of patients receiving only 
conventional therapy, but yet without assessing the outcomes. Hence, the ratio of cost to outcome is 
not yet clear (40). 
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Discussion 
 
On the whole, outcome studies document relatively uniform results: In patients undergoing 
homeopathic treatment in routine care, relevant clinical improvements are observed, if compared to 
conventional care with often similar outcomes, but with fewer adverse effects and, in half of all health 
economic studies, lower costs. 
 
It is important to understand that uncontrolled observational studies cannot examine whether high-
potency homeopathic remedies are more effective than placebos. Outcomes from clinical routine are 
reported. Such outcomes have to be investigated with care and can be influenced by a number of 
factors – drug effects, suggestive effects, expectations, therapeutic consultations, regression toward 
the mean, and concomitant (non-homeopathic) therapies, amongst others. 
 
The strengths of outcome studies, however, are that they allow to report on the outcomes of 
homeopathy in everyday conditions, portraying a good picture of the experiences gained by 
homeopathic patients and therapists in the daily routine. 
 
 
Conclusion 
 
Under routine conditions, clinically relevant improvements in symptoms and quality of life are reported 
by the majority of homeopathic outcome studies. From a pragmatic perspective it can be concluded 
that patients experience a clinical benefit. Methodologically, however, a causal relationship (efficacy) 
between drug therapy and outcomes cannot be investigated in these studies. 
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Results of original RCTs with individual 
homeopathy and high potencies versus 
placebo and standard treatments 
 
Klaus von Ammon, Loredana Torchetti, Martin Frei-Erb 
 
_________________________________________________________________________________ 
 
 
Purpose 
 
To compile an overview of the specific effects of individually prescribed ultramolecular medicines 
(classical homeopathy with high potencies ≥C12) compared with placebo or standard therapy when 
used in patients requiring treatment. 
 
 
Method 
 
A search for literature in published meta-analyses and the “Medline” database (search criteria: 
“homeopath*” AND “RCT” AND publication date 01/01/2012-31/12/2014) resulted in high-quality 
(minimum criterion: Jadad1 score ≥3), peer-reviewed original publications on randomised controlled 
trials (RCTs) into the effect of individually prescribed ultramolecular medicines (potency ≥C12) which 
were collated for the purpose of a descriptive assessment. Books or book contributions, dissertations 
or conference articles were excluded from this analysis, as were pilot studies, studies that were not 
double-blind, studies with a dropout rate of >20%, studies with laboratory or surrogate parameters, 
and prevention studies. The original studies were used, if possible, or the data extracted from meta-
analyses. 
 
 
Result 
 
Based on the publications by Linde 19972, Linde and Melchart 19983, Clausius 19984 and Shang 
20055, RCTs of good methodological quality fulfilling the minimum criterion of Jadad score ≥3 were 
identified. In addition, all peer-reviewed RCTs into classical homeopathy could be selected from 
Mathie 20136 and 20147, and an updated Medline search (period 2012-2014) was performed. 
Altogether, 71 RCTs (without duplicate entries) were identified from the period 1982 to 2014. Of these, 
a total of 62 trials were ruled out (for details, see Table 1, page 20): 26 due to the use of molecular 
substances (potency < C12), 14 pilot studies, 11 single-blind studies, five due to laboratory/surrogate 
parameters, and six for other reasons (two due to a lack of peer review, two due to the preventive use 
of homeopathy, and two due to a high dropout rate). 
 
A total of 24 to 126 patients took part in the remaining nine trials (Table 2, page 21), with a mean 
number of 64 (SD=31, median 64). The clinical spectrum comprised three studies of diarrhoea, and 
one study for each of the other diagnoses. In four studies, homeopathy was used as an add-on to 
standard treatment (Frass 2005I3, Jacobs 1993I5, Jacobs1994I6, Jacobs 2000I7). In all nine studies, 
homeopathy was compared against placebo. The clinical endpoint of the studies varied between five 
days and 1.5 years. The intention-to-treat (ITT) analysis is a standard. 
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In meta-analyses of RCTs, the study quality (risk of bias) is assessed by evaluating the internal 
validitiy. For this purpose, different instruments were used in the various meta-analyses: Linde 19972, 
Linde and Melchart 19983, and Clausius 19984 applied the – now outdated – Jadad score1 (maximum 
5 points, cut-off for low risk of bias ≥3) and their own scale to assess internal validity (maximum 6 or 7 
points, cut-off ≥4 or ≥5 points; for details see Table 3, page 23). In the case of Shang 20055, the study 
quality was judged on the basis of similar criteria to Jadad (higher quality = double-blinding and 
adequate randomisation). Mathie 20147 used today’s commonly applied Cochrane method8, 
supplemented by differentiated classification of the bias categories. For the purposes of comparison, 
we evaluated the quality of the studies by Frei 2005I4 and Lökken 1995I8 using the Cochrane criteria 
and according to Mathie’s classification. Some studies were thus evaluated with different tools. The 
methodological quality of most of the studies was found to be consistent in the various meta-analyses, 
with the exception of Jacobs 2000I7 (Shang low, Mathie high risk of bias) and Whitmarsh 1997I9 (high 
risk of bias in Mathie, and Shang, good quality in Linde and Melchart). Only the study by Jacobs 
1994I6 was judged by Mathie to offer reliable evidence. In our opinion, the study by Frei 2005I4 can 
likewise be deemed reliable. 
 
On the whole, whilst the study quality is not entirely optimal, it is satisfactory. Of the nine studies, only 
Frei 2005I4 revealed a low risk of bias according to the Cochrane criteria; in five studies the risk of bias 
was deemed uncertain, and in three the potential for bias was rated as high. The results of these 
studies must therefore be interpreted with certain reservations. 
 
To compare the studies and subject them to meta-analysis, the results of the original studies were 
converted into effect size measures, such as into odds ratios (ORs). If the accompanying 95% 
confidence interval (CI) did not include 1, it was assumed that one group was superior to the other. 
 
Of the eight RCTs with a calculated OR, six indicated that classical homeopathy was superior to 
placebo, whereas the situation was reversed in two studies (Table 4, page 23). Given the small 
sample sizes in all the individual studies, however, the confidence intervals were too wide to be able to 
suggest that the effect of homeopathy or placebo was clearly superior. The only exception was the 
study by Frass 2005I3, the result of which clearly favoured homeopathy. 
 
Whereas no OR was given in the case of Frei 2005I4, the significance test to ascertain group 
differences was applied. It indicated superiority for classical homeopathy over placebo, even if such 
significance tests do not constitute measures of effect size and thus are not particularly suitable for 
making a summarised assessment. 
 
By restricting the review to the studies with the best quality (reliable evidence) according to Mathie’s 
criteria omly, the OR in Jacobs 1994I6 then favoured classical homeopathy whilst the CI started 
precisely at 1. Homeopathy also appeared to be superior to placebo in Frei 2005I4, even if no OR with 
CI was available for making a direct comparison. 
 
 
Discussion 
 
As suggested by the majority of systematic reviews and meta-analyses performed to date, there is 
some evidence that classical homeopathy is superior to placebo. Also consistent with previous meta-
analyses is the fact that the quality of the studies is not satisfactory right through. By applying very 
strict parameters (low or uncertain risk of bias, as per Mathie 20147), the number of usable studies is 
reduced to six, with the remaining three revealing a high risk of bias in accordance with Mathie 20147. 
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Given that these results were obtained from relatively few studies and small sample sizes, the 
following conclusions must be interpreted with caution (cf. Mathie 20147). 
 
The criterion of this review is the individual application of high potencies, which were used for different 
diagnoses with varying outcome measures and endpoints. In this respect the available data are 
inhomogeneous, allowing only for descriptive analysis. 
 
It is surprising that all the studies were placebo-controlled, there were no comparative studies with 
standard therapy only, i.e. standard therapy without placebo, and that in a large number (4 out of 9) of 
studies homeopathy was used as an add-on. This reflects the experimental approach of most of the 
studies and invokes the question of transfer and applicability into daily practice. The broadness of the 
diagnostic spectrum, covering acute and chronic, mild (Lökken 1995I8) to severe (Frass 2005I3) 
conditions, is just as surprising. Apart from the three studies by JacobsI5-I7 into childhood diarrhoea, 
none of these studies has as yet been replicated. 
 
To achieve more definitive results, future clinical studies should be conducted prospectively with larger 
sample sizes and methods that closely reflect the clinical routine. 
 
This review did not consider any non-peer-reviewed studies into classical homeopathy, nor any 
studies that employed non-individualized methods of homeopathy – clinical, complex homeopathy, 
complex (integrative) treatments and isopathy – which are covered by the pool of experience in 
applied homeopathy. 
 
 
Summary 
 
In the last 25 years, a number of good-quality studies into individual homeopathy and ultramolecular 
medicines have been published subsequent to peer review in high-level, Medline-indexed journals. 
The majority (7 out of 9) indicate that these medicines have a specific effect, even if the sample size of 
the individual studies was generally too small to demonstrate, on its own, that they were clearly 
superior. 
 
A similar overview should be produced for non-peer-reviewed studies (n=15 in Mathie 20136) and non-
individually prescribed homeopathic treatment (n=279 in Mathie 20136). 
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Table 1 Sources and primary exclusion criteria of RCTs not included in the overview 
 
No. 
  
Authors 
  
Year 
 
Sources  Primary reason for exclusion 
Linde 
1997 
Clausius 
1998 
 
Linde & 
Melchart 
1998 
Shang 
2005 
Mathie 
2013 
Mathie 
2014 
Medline 
search 
(2012-2014)  
Potency 
<C12 
Pilot 
study 
Single- 
blind 
Lab/ 
surrogate 
parameters Other 
E1 Adler 2011     x    x     
E2 Adler 2013      x x    x   
E3 Andrade 1991 x x x   x   x     
E4 Awdry 1996   x          x1 
E5 Bell 2004      x      x  
E6 Bell 2004      x      x  
E7 Bell 2004      x      x  
E8 Bell 2004      x   x     
E9 Brien 2011      x   x     
E10 Brigo 1991   x          x1 
E11 Carlini 1987   x   x   x     
E12 Cavalcanti 2003      x   x     
E13 Chakraborty 2013      x     x   
E14 Chakraborty 2013      x     x   
E15 Chand 2014       x     x  
E16 Chapman 1994 x x x x     x     
E17 Chauhan 2014       x   x    
E18 de Lange 1994 x x x   x   x     
E19 Fisher 1986  x       x     
E20 Fisher 1989  x x      x     
E21 Fisher 2001      x   x     
E22 Fisher 2006      x    x    
E23 Gaucher 1994      x   x     
E24 Gerhard 1997     x     x    
E25 Gmünder 2002     x      x   
E26 Haila 2005      x     x   
E27 Harrison 1999     x     x    
E28 Hitzenberger 1982  x   x    x     
E29 Jacobs 2001    x  x    x    
E30 Jacobs 2005      x   x     
E31 Jacobs 2005      x   x     
E32 Jansen 1992      x    x    
E33 Kainz 1996   x   x   x     
E34 Katz 2005      x   x     
E35 Kuzeff 1998   x   x      x  
E36 Mouräo 2013       x    x   
E37 Mouräo 2014       x    x   
E38 Mousavi 2009      x     x   
E39 Naude 2010      x   x     
E40 Oberai 2013      x     x   
E41 Paterson 2003     x     x    
E42 Peckham 2014       x  x     
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E43 Rastogi 1999      x   x     
E44 Relton 2009     x     x    
E45 Relton 2012       x   x    
E46 Saha 2013      x     x   
E47 Sajedi 2008      x   x     
E48 Schreier 1997     x     x    
E49 Schwab 1990 x x x       x    
E50 Siebenwirth 2009      x   x     
E51 Sinha 2012       x    x   
E52 Steinsbekk 2005      x       x2 
E53 Steinsbekk 2005     x        x2 
E54 Straumsheim 2000   x   x   x     
E55 Thompson 2005      x    x    
E56 Thompson 2011     x     x    
E57 van Erp 1996     x        x3 
E58 Walach 1997   x x  x   x     
E59 
Weatherley-
Jones 2004      x   x     
E60 White 2003      x   x     
E61 Witt 2009     x        x3 
E62 Yakir 2001      x    x    
Remarks 
1
 No peer review 
2
 Prevention 
3
 High dropout rate: E57 van Erp 1996: 26%, E61 Witt 2009: 53% 
 
 
 
Table 2 Description of included trials  
 
No. Authorship Year Diagnosis n ITT n PP Duration Study group Control group 
I1 Bonne 2003 Anxiety disorder 44 39 10 weeks HOM PLA 
I2 Chapman 1999 Traumatic brain injury 61 50 4 months HOM PLA 
I3 Frass 2005 Sepsis 70 67 180 days Standard + HOM Standard + PLA 
I4 Frei 2005 ADHD 62 57 180 days HOM PLA 
I5 Jacobs 1993 Acute diarrhoea in children 34 33 ≤ 6 days Standard + HOM Standard + PLA 
I6 Jacobs 1994 Acute diarrhoea in children 92 81 ≤ 5 days Standard + HOM Standard + PLA 
I7 Jacobs 2000 Acute diarrhoea in children 126 116 5 days Standard + HOM Standard + PLA 
I8 Lökken 1995 Removal of wisdom teeth 24 24 5 days HOM PLA 
I9 Whitmarsh 1997 Migraine 63 60 4 months HOM PLA 
Remarks 
ITT = intention-to-treat analysis; PP = per protocol analysis; ADHD = attention deficit hyperactivity disorder; 
HOM = homeopathy; PLA = placebo; standard = standard treatment 
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Table 3 Risk of bias of the included trials  
 
No. Authorship Year 
RoB Linde 
1997: 
Jadad 
(5; ≥3)1 
 
RoB 
Linde 
1997: 
IV 
(7; ≥5)2 
RoB 
Clausius 
1998: 
MV 
(10; ≥5)3 
RoB 
Linde & 
Melchart 
1998: Jadad 
(5; ≥3)1 
 
RoB 
Linde & 
Melchart 
1998: 
IV 
(6; ≥4)4 
Study 
quality 
Linde & 
Melchart 
19985 
RoB 
Shang 
20056 
RoB 
Mathie 
20147 
RoB after 
Mathie8 
I1 Bonne 2003        Uncertain (B3)  
I2 Chapman 1999       Low Uncertain (B1)  
I3 Frass 2005        Uncertain (B2)  
I4 Frei 2005         Low (A) 
I5 Jacobs 1993 3 3.5 7 3 3 B High High(C1.4)  
I6 Jacobs 1994 5 6 9 5 5 A Low Uncertain (B1)9  
I7 Jacobs 2000       Low High (C2.0)  
I8 Lökken 1995 5 6 5 5 5.5 A   Uncertain (B1)10 
I9 Whitmarsh 1997    4 4 A High High (C1.4)  
 
Remarks 
RoB = risk of bias; IV = internal validity; MV = model validity; MA = meta analysis. 
1
 Jadad 1996: maximum 5 points (cut-off ≥3) for: 1) Randomisation; 2) Adequate randomisation; 3) Double-blind; 
4) Adequate blinding; 5) Reporting of dropouts and discontinuations. 
2
 Internal validity Linde 1997: maximum 7 points (cut-off ≥5) for: 1) Randomisation; 2) Adequate randomisation; 
3) Comparability of the groups before treatment; 4) Blinding of the patients; 5) Blinding of examining 
physicians; 6) Selection error after onset of treatment 7) Adequate statistical analysis. 
3
 Model validity Clausius 1998: maximum 10 points (cut-off ≥5): 1) Compliance with similarity principle (0-5 
points); 2) Validated drug prescribing (0-1); 3) Level of trust in prescribing (0-1); 4) Medicine known to 
homeopathy (0-1); 5) Unum remedium (0-1); 6) Specialist homeopathic expertise of the physician (0-1). 
4
 Internal validity Linde & Melchart 1998: maximum 6 points (cut-off ≥4), precise criteria not determinable: 
5
 Study quality Linde & Melchart 1998: A) Good methodological quality likely; B) Major deficiencies unlikely; C) 
Significant minor or moderate problems; D) Not evaluable/major deficiencies. 
6
 Shang 2005: low risk of bias = double-blind, adequate randomisation (i.e. adequate generation of 
randomisation sequence and adequate masking of randomisation). 
7
 Risk of bias Mathie 2014: 7 Cochrane ranges 1) Adequate generation of randomisation sequence; 2) Adequate 
masking of randomisation; 3a) Blinding of participants and study personnel; 3b) Blinding of examiners; 4) 
Completeness of outcome data; 5) Selective reporting; 6) Other biases. 
A = low risk of bias in all seven ranges; Bx = uncertain risk of bias in x ranges, low risk of bias in all other 
ranges; Cy.x = high risk of bias in y ranges, uncertain risk of bias in x ranges, low risk of bias in all other 
ranges. 
8
 The studies whose risk of bias had not already been evaluated in the meta-analysis by Mathie 2014 were 
assessed according to the Cochrane criteria and evaluated using the Mathies classification. 
9
 Reliable study as per Mathie 2014, i.e. at least bias category B1, and free of bias in the Cochrane ranges 1, 2, 
3a and 3b. 
10
 Risk of bias in Lökken 1995 (as per Cochrane ranges): unclear in range 1 (i.e. unclear whether the 
randomisation sequence was adequately generated), and low risk of bias in all other ranges. 
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Table 4 Results of included studies 
 
No. Authorship Year 
 
OR 
Linde 1997 & 
Clausius 1998 
(>1 favours HOM)1 
CI 
Linde 
19971 
OR 
Shang 2005 (<1 
favours HOM)2 
CI 
Shang 
20052 
OR Mathie2014 
(>1 favours 
HOM)3 
CI 
Mathie 
2014 
Outcome of 
testing for group 
differences4: 
I1 Bonne 2003         0.87 0.28-2.73  
I2 Chapman 1999     approx. 1
5 incl. 1 1.986 0.72-5.49  
I3 Frass 2005         3.13 1.10-8.86  
I4 Frei 2005            HOM>placebo
7 
I5 Jacobs 1993 1.97 incl. 1 <1 incl. 1 n.i. n.i.  
I6 Jacobs 1994 2.24 incl. 1? <1 incl. 1? 2.22 1.00-4.94  
I7 Jacobs 2000     <1 incl. 1? n.i. n.i.  
I8 Lökken 1995 0.72 incl. 1         
I9 Whitmarsh 1997     approx. 1 incl. 1 1.72 0.69-4.34  
 
Remarks 
OR = odds ratio; CI = 95% confidence interval; HOM = homeopathy; MA = meta-analysis 
1
 OR and CI for Linde 1997 are depicted on a graph only; these ORs (without CIs) are reported for Clausius 
1998, on the other hand, 
2
 Shang 2005: OR and CI are presented on a graph only. 
3
 n.i.= not included in the meta-analysis for Mathie 2014, as data could not be extracted. 
4
 In the case of the study by Frei 2005 not yet included in a meta-analysis, a report is provided on the outcome 
of statistical testing for group differences. 
5
 Outcome: impaired activity. 
6
 Outcome: symptoms. 
7
  Frei 2005: Crossover study to compare homeopathy against placebo; the linear mixed model delivers a 
significant within-person difference in favour of homeopathy (-1.67 points on the symptom-outcome scale, with 
a 95% CI of -3.316 to -0.016; p=0.0479). 
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Methodological problems of randomised 
double-blind trials in homeopathic research 
 
Klaus von Ammon, Curt Kösters 
 
_________________________________________________________________________________ 
 
 
RCTs (randomised controlled trials) are aimed at examining the efficacy of medical treatments. They 
entail experiments with (at least) two groups of patients or volunteers randomised to either the study 
group (under treatment to be studied) or the control group. The control treatment thereby comprises 
placebo or the best available therapy to date, or the study treatment is administered as an add-on to 
the best proven treatment. Multi-group comparisons can therefore be performed. 
 
The aim is to control any external confounding factors (such as the study location, methods of 
administration etc.) as far as possible, or ensure that they do not differ between patients, so as to 
create the same conditions for the study groups. To control the “internal” – known and unknown – 
confounding factors amongst the subjects (e.g. expectations, predispositions, responsiveness), 
randomisation is used: it can thus be assumed that such factors are balanced out between the groups, 
or will differ only through coincidence, respectively. In such a way, the specific net effect of the 
treatment to be studied can be determined. 
 
Such a study is deemed double-blind if neither the study subjects nor the investigators know to which 
study group a subject belongs. Triple-blind refers to a study design in which the rater also is unaware 
of the randomisation and the nature of the different treatments. 
 
These types of study are generally chosen when investigating new medicinal products and are 
regarded as the “gold standard” – especially if the design is at least double-blind. 
 
The RCT is surpassed at the top of the evidence pyramid (evidence-based medicine or EBM) only by 
a methodological review of such RCTs (meta-analysis). 
 
With respect to the understanding of methodological problems, it must be noted that epistemologically 
RCTs are based on the paradigm of the classical natural science experiment. In such an experiment, 
all known variables are kept constant and only one input variable is modified. The resulting 
reproducible change in the output variables leads not only to the conclusion of a causal relationship 
between the input and output variables, but at the same time also permits this relationship to be 
quantified precisely. 
 
If such an experiment cannot be fully reproduced in each individual case, it must be assumed that 
further, as yet unidentified variables exist. Before the experiment is sensibly repeated, these variables 
must be identified and eliminated. 
 
The adaptation of this experimental approach to therapeutic research (and here in particular to 
pharmacotherapy) has brought with it methodological limitations, however: 
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• Biological organisms exhibit individual reactions – full reproducibility in an individual case 
generally cannot be achieved. Such a requirement has been abandoned in favour of a statistical 
statement concerning the differences in the respective group as a whole.1 
• Repetition in an individual case is replaced through replication of the study as a whole. 
• To keep the variables constant and to control them, randomisation is added – it should 
compensate for the potential internal “confounding factors”. 
• On account of the rising number, the inconsistent results and incomplete reproducibility of 
studies and trials, they are summarised in meta-analyses. 
 
What remains is the requirement that the greatest possible homogeneity be achieved within the study 
groups. Resulting problems in particular, but also further methodological problems, are still a topic of 
discussion, as is the value of this concept to medical practice. 
 
In terms of medical practice, RCTs come under criticism for the following reasons, amongst others: 
 
1. As experiments, RCTs represent an essentially different situation to that encountered in 
everyday routine medical consultation. 
2. The behaviour of the principal investigator could – from the design of the study alone – be 
altered by his/her expectations (Rosenthal effect). 
3. The individuals involved are aware of this difference and possibly behave differently 
(Hawthorne effect for study subjects). 
4. Different reactions from one individual to the next cannot be reflected by the statistical 
statement.2 
5. Any resulting statistically significant differences are no guarantee that the obtained findings are 
clinically relevant. 
6. The applicability and relevance to routine practice with mostly multimorbid, old, (very) young, 
female, or pregnant patients, for instance, prove problematic, as the study subjects are often 
young men. 
7. Adverse effects or interactions with other medicinal products cannot be monitored during the 
usually short period of study. 
8. Long-term effects thus can only be recorded insufficiently and are systematically undervalued. 
Long-term effects can look very different, and under certain circumstances also contrast with 
the short-term effects. 
9. Non-pharmacological treatment methods can be investigated only to a limited extent in double-
blind studies.3 
                                                 
1
 A probability of error must thereby be taken into consideration. A probability of error of 5% (or 1% and 0.1%, 
respectively) is now common. 
2
 Georg Ivanovas raised the eloquent question in relation to a double-blind study into the influence of the firmness 
of a mattress on chronic back pain (Kovacs FM et al: Effect of firmness of mattress on chronic non-specific low-
back pain: randomised, double-blind, controlled, multicentre trial. Lancet 2003, 362: 1599–604), namely whether 
all patients should sleep on a moderately firm mattress, including the 10% who experienced increased pain from 
such a mattress and were more comfortable on another. Similar issues resulting from individual reactions have 
also been seen with medicinal products, however. 
3
 This proves problematic if, when writing a guideline on depression, the evidence pertaining to pharmacological 
measures must be weighed against that of psychotherapeutic interventions. 
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10. Complex therapeutic strategies with individualised elements (as is common practice today in 
pain therapy, for instance) cannot be investigated appropriately by means of the RCT.4 
11. The applicability of this experimental approach to entire therapeutic systems has not yet been 
examined systematically, let alone validated. 
 
The classic double-blind study is designed with a specific, almost experimental study scenario in mind: 
one medicinal product is tested in one indication. It is very well suited to the examination of such a 
focused question (with the mentioned limitations). 
 
If this more or less successfully implemented strategy for conventional pharmaceutical research is 
adapted to homeopathic research, a number of other problems emerge which are inherent to the 
research subject and possibly, in turn, will necessitate adaptation of the research tool – and limit its 
validity or applicability, respectively. Some of these issues are already recognised5, but possibly have 
not yet been methodologically examined to an adequate degree. 
 
Problems arise with the application of the methodological tool of double-blind RCTs in homeopathic 
research due to individualisation, due to the iterative approach to finding an appropriate agent and the 
assessment of the course, and due to the different way in which therapeutic success is evaluated in 
homeopathy. 
 
Changes in symptoms can occur as a result of the natural course of the disease but also, in particular, 
as a reaction to a previously administered medicine. Successive approximation solutions are thus 
involved here, in the sense of an iterative approach. 
 
The course during homeopathic treatment is evaluated largely on the basis of the change in well-
being, as well as the relevant clinical symptoms. A marked improvement in well-being, albeit without 
any major improvement in the clinically relevant symptoms to begin with, is a justified reason for 
waiting – because experience has shown that an improvement in clinically relevant symptoms will 
follow. 
 
 
Problems due to individualisation 
 
RCTs with adequate individual remedy finding and prescribing in line with classical homeopathic 
principles have seldom been conducted (see contribution by Klaus von Ammon, Loredana Torchetti, 
Martin Frei-Erb: Results from original RCTs with individual homeopathy and high potencies versus 
placebo and standard treatments, with excluded studies therein). 
 
In a study with individual remedy selection (as is standard practice in classical homeopathy), the 
overall outcome is inevitably poorer than the result from the individual agent with the highest degree of 
probability if the different remedies available for selection do not offer the same – or at least roughly 
the same – degree of probability. 
 
The degree of probability – if initially ignoring the involved therapist and his/her level of expertise – 
depends largely on the information available on the individual agents and their reliability. 
                                                 
4
 In complex therapeutic strategies, the interplay of different treatments (e.g. pharmaceuticals, physiotherapy, 
relaxation techniques, psychotherapy, acupuncture) individually adapted to suit the patient in question are 
expected to deliver the therapeutic effect, rather than a single intervention. 
5
 Gaus W, Högel J. Studies on the efficacy of unconventional therapies. Problems and designs. 
 Arzneimittelforschung. 1995 Jan; 45(1):88–92. 
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The information available on the individual agents differs considerably, ranging from remedies with 
more than 1,000 known symptoms (originating mainly from drug proving and confirmed, moreover, by 
clinical experience – if taken together a criterion for high validity in homeopathy) to those with fewer 
than 10 known symptoms, which in addition result from clinical experience only and hence are of low 
validity in homeopathy. 
 
In the clinical routine, this difference in the level of knowledge about medicines and the resulting, 
differing degree of probability are a much less serious problem (see above). The effect size of a study, 
which precisely evaluates an intervention, is therefore lower than the effect of an individual 
homeopathic treatment in clinical routine. Under the pressure of a study to offer the “optimal” 
prescription spontaneously (instead of the practical approach to approximation), a negative Hawthorne 
effect could in fact emerge. 
 
Besides, therapists selecting medicines on an individualised basis cause an additional, fundamental 
methodological problem. The double-blind studies of conventional medicine themselves offer only 
limited reproducibility compared to classical physical experiments, because aside from the medicinal 
products as the actual study variables, the patients and their individual reactions are also involved. 
The therapists, as the third independent variable, additionally hamper replication – including 
replication by independent examiners, in particular. 
 
Proposed solutions: 
• Limitation of the choice of agents and introduction of a standardised treatment protocol is 
potentially suitable as a means of minimising the “therapist” variable. In an open pilot phase, 
the problem of differing probabilities can potentially be minimised. A restriction to the 
effectiveness of treatment vis-à-vis the results from everyday practice must probably be 
accepted. In case of simple, acute conditions this approach would appear to be justifiable 
based on experience to date; in chronic conditions the same would certainly then apply if at 
the same time an exclusion criterion is introduced for patients with symptoms that do not 
correspond to those of one of the approved agents – an exclusion criterion that at the same 
time clearly narrows the external validity (validity of the study for average patients). 
• One innovative solution is the idea of an open treatment phase followed by the actual double-
blind study with the inclusion criterion of “responder” (Bell: fibromyalgia 6 ; Frei: ADHD 7 ). 
However, a large proportion of the therapeutic effect already exhausted in the open treatment 
phase will no longer be captured by the double-blind study. Whether this concept can be 
successfully applied to other indications and other prescribing strategies also has not yet been 
fully explained or examined. Yet again, external validity is limited in this case by the inclusion 
criterion. In the design addressed specifically here, moreover, undesirable crossover effects 
(e.g. take-over instead of wash-out effects) cannot be completely ruled out. Provisionally, this 
concept must still be regarded as experimental by nature. 
• An interesting, but certainly also still experimental – and largely untested – approach is the 
“N=1 study” with the option of consolidated meta-analyses.8 In this case individualisation is not 
a methodological problem. Somewhat unclear in this study design is the documentation of 
changing prescriptions (see Iteration below); also unclear is the external validity. 
                                                 
6
 Bell I, Lewis D, Brooks A, Schwartz G, Lewis S, Walsh B, Baldwin C. Improved clinical status in fibromyalgia 
patients treated with individualized homeopathic remedies versus placebo. Rheumatology. 2004; 43:577–582. 
7
  Frei H, Everts R, von Ammon K, et al. Homeopathic treatment of children with attention deficit hyperactivity 
disorder: a randomized, double blind, placebo controlled crossover trial. Eur J Pediatr. 2005; 164:758–767. 
8
  Teut M, Linde K. Scientific case research in complementary and alternative medicine-a review. Complement 
Ther Med. 2013 Aug; 21(4):388–95 
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• The solution that appears to come closest – whilst also the oldest: To permit consecutive 
prescriptions with consistent blinding (Walach, headaches9) is probably, methodologically, 
more problematic (see Problems due to iteration below). 
 
 
Problems due to iteration 
 
To date no sufficient methodological evidence has been forthcoming to demonstrate that a double-
blind study is a suitable experimental tool for evaluating several different successive and (within the 
meaning of iteration) coordinated prescriptions. Successive prescriptions permitted in a double-blind 
study could intensify the blurring of individual prescriptions. 
 
It is recommended, therefore, to apply the double-blind study initially to individual interventions only 
(including repetitions of the same agent). This tends to restrict the applicability of the double-blind 
study in homeopathic research to simple, acute diseases, however. 
 
 
Problems due to the outcome 
 
Unlike conventional pharmaceuticals, homeopathic remedies are not suitable for forcing the organism 
in question into a specific state – the postulated effect is stimulated self-regulation. The reactions thus 
induced are far more individual in their nature and course over time compared to the response to 
conventional pharmaceuticals. Assessment of the course in clinical practice is therefore much more 
strongly related, in the case of homeopathy, to the symptoms as a whole and also, in particular, to 
changes in well-being. 
 
In the planning of a study this alternative approach to assessing the course must at least be 
considered – this requirement again tends to conflict, however, with the methodologically 
standardised, pre-defined examination times for the respective primary endpoints of a study.10 
 
Also to be considered, however, are other clinical courses and how they can be given adequate 
consideration in the design of a study.11 
 
These issues are also mostly relevant to chronic indications and largely negligible in the case of acute 
diseases. 
 
 
 
 
                                                 
9
  Walach H, Häusler W, Lowes T, Mussbach D, Schamell U, Springer W, Stritzl G, Haag G. Classical 
homeopathic treatment of chronic headaches. Cephalalgia. 1997; 17:119–126. 
10
  If headache is the primary endpoint, but the mood and energy levels of a patient initially clearly improve, then 
in practice (and from the perspective of the patient) this is regarded as a marked improvement – in a study it is 
not. 
11
  The outcome of a study into the treatment of neurodermatitis, compared directly against ongoing cortisone 
treatment, is predictable: the effect of cortisone is faster and far better than that of a homeopathic treatment. 
Patients who seek homeopathic treatment for neurodermatitis are also aware of this fact. This is not the 
question that needs to be answered by a study, therefore. As far as the comparison between homeopathic 
treatment and cortisone therapy is concerned, it would be much more interesting if it were conducted in each 
case three weeks after discontinuing the last agent (in both study groups). In turn, however, the question 
arises whether this scenario also offers an appropriate and fair design from the perspective of conventional 
medicine. 
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Other problems 
 
Further phenomena characteristic of homeopathy, such as primary aggravation or a symptom shift 
(centripetal shift in symptoms vs. Hering’s law), also have not yet been considered by the design or 
the analysis of studies, respectively. The individual development of such phenomena also conflicts at 
this point with the rigid scheduling of follow-up appointments required for the purpose of statistical 
analysis. But this, also, tends to be more relevant to chronic conditions. 
 
Entanglement effects were suggested by Walach; hence, they should be accounted for planning a 
study. To date, however, neither the existence nor the power of such effects have been adequately 
examined or proven. 
 
Appropriate research relating to these problems would be useful in the field of conventional 
pharmacology. The question as to possible substance-, remedy- or drug-specific effects in the placebo 
group (including proper storage of the products) has not yet been investigated. Clinical experience 
tends to suggest that this phenomenon is not particularly relevant. 
 
Meta-analyses of diverse diagnoses in the strict sense of the definition (homogeneous total 
population) tend to be questionable from the basic perspective of methodology. Such vast meta-
analyses could be practical as an extension to systematic review. 
 
 
Implications for homeopathic clinical research 
 
Better and more extensive data are required with respect to routine homeopathic practice. 
Conclusions can be drawn from such data with a view to study planning: useful indications, effect 
sizes, appropriate study sizes and durations, along with data on the probability of selecting individual 
agents. Comprehensive and unselected case documentation will most likely deliver such data. 
 
So far, study planning sometimes appears to be founded upon estimations and individual clinical 
advisers and their personal experience. There is room for improvement, accordingly, when it comes to 
communication between practice and research. And at least until valid data from everyday practice are 
available, extensive pilot phases are recommendable as part of study planning (see above). 
 
The highly deficient development of theories in homeopathy should be stimulated. However, there is 
still a need for clarification with respect to individual research tools (appropriately modified RCT 
designs, e.g. by excluding non-responders and N=1; see above). 
 
It is not possible to demonstrate at present, however, that a double-blind study, especially with primary 
blinding, is a suitable research tool for examining homeopathic treatment in any given indication – 
especially in chronic indications. 
 
The justified, understandable and as yet inconclusively resolved question, namely “what contribution 
do context effects make to the clinical efficacy of homeopathy?”, in turn can be answered only, and 
exclusively, by (adequately elaborated) double-blind studies. 
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With this in mind, but also in the light of the long-standing and not only scientific debate surrounding 
homeopathy12 – a debate that has long since become a vehement social dialogue on a global scale – 
the question arises whether research should not concentrate on the central point of this debate. 
 
The clinical effectiveness of the method is not denied, even by sceptics and scientific critics. This 
debate does not (or at least not primarily) revolve around whether a homeopathic treatment is effective 
in one or another indication, but whether this clinical effectiveness can be attributed to and thus 
explained by a specific effect (efficacy) caused by the medicines applied (plausibility paradox, see 
footnote 13 below). High potencies, above all, naturally attract considerable attention. 
 
Quite clearly, the relevant number of clinical studies performed in recent decades did not deliver a 
definitive conclusion13. 
 
Perhaps the two essential questions raised here – “In which indications is homeopathic treatment 
effective?” and “What is the basis for the effect of homeopathic treatment?” – should be addressed 
separately. And the second question should be answered by developing independent treatment 
models. Distinguishing between questions and developing methodologically appropriate models are 
also suitable approaches when considering theoretical scientific aspects. RCTs in the field of 
conventional pharmacology address the question whether a specific medicine is effective in a specific 
indication. RCTs in homeopathic research address the (clinical) effectiveness of the method, the 
efficacy (specific effect) of the drug, and the mechanism of action. 
 
These therapeutic models should then be replicated multiple times – by different examiners – ideally 
with a pre-defined number of replications. 
 
Given the methodological problems arising from individualisation and iteration, the therapeutic models 
most appropriate here are those based on a limited number of agents which are prescribed according 
to a rigid regimen. Clinical situations in which, as a rule, the same agent is prescribed 
homeopathically, are ideal. For this reason alone, acute diseases/conditions must be clearly 
prioritised. 
 
Very simple models (one condition/one agent) would also offer the advantage that they can potentially 
also be analysed and replicated by examiners who have no prior knowledge of homeopathy. A pre-
defined number of replications would also permit a falsification criterion to be established. If the 
negative hypothesis applies, the results from replications should equate to the probability of chance. 
 
Testing of the models in appropriate pilot studies is advisable, at least until a clinical database in the 
form of unselected case documentation is available. 
 
 
 
 
                                                 
12
   In 2005, the esteemed scientific journal The Lancet officially announced “The end of homeopathy” in its 
editorial. 
13
   “All relevant published reviews [...] reveal that the majority of the available studies produced positive results 
(this also applies to that by Shang et al.!). At the same time, it cannot be denied that positive results are not as 
common from studies with good methodology as from those that are not so good. Naturally this means that 
positive results can certainly also be found in the good studies. The debate amongst clinical researchers 
therefore is not whether positive evidence is derived from placebo-controlled studies, but whether such 
evidence is sufficient to prove the efficacy of homeopathy in view of the low plausibility from the perspective of 
natural science.” (Prof. Klaus Linde, Munich Technical University, personal communication 2007). 
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Simple models that have already been tested are, for example: 
• Treatment of childhood diarrhoea (Jacobs)14 
• Treatment of respiratory patients with high-potency potassium dichromate (Frass)15 
 
The treatment of hay fever with pollen (Reilly)16 is also, in principle, a very suitable isopathy model, 
given its simplicity, for investigating the effect of potentised substances. 
 
Beyond these therapeutic models, and without unduly influencing the therapeutic setting, the question 
of which indication is successfully treated by homeopathy can be answered scientifically to current 
methodological standards, depending on the indication, by epidemiological studies, cohort studies, 
randomised unblinded studies, and also by unselected case series. This applies in particular to 
chronic illnesses. 
 
For reasons of logic, future meta-analyses will then be based predominantly on model studies that are 
easy to replicate, and their respective replication(s). 
 
 
                                                 
14
  Jacobs J, Jonas WB, Jimenez-Perez M, Crothers D: Homeopathy for childhood diarrhea: combined results and 
metaanalysis from three randomized, controlled clinical trials. Pediatr Infect Dis J 2003; 22(3):229–234. 
15
  Frass M, Dielacher C, Linkesch M, Endler C, Muchitsch I, Schuster E, Kaye A. Influence of potassium 
dichromate on tracheal secretions in critically ill patients. Chest. 2005; 127:936–41 
16
 Reilly D, Taylor M, Beattie N, et al., Is Evidence for Homoeopathy Reproducible? Lancet, December 10, 1994, 
344:1601–6. 
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Meta-analyses in homeopathic clinical 
research 
 
Jens Behnke 
 
_________________________________________________________________________________ 
 
 
1. Introduction 
 
The idea behind evidence-based medicine (EBM) is that one or more meta-analyses of high-quality, 
randomised clinical trials will furnish reliable data on the efficacy of a therapeutic method. A treatment 
for which sufficient positive data are available within this context is proven by the highest level of 
evidence, namely Ia.1 In response to the question whether and to what extent a particular method 
should be used in the clinical routine, it is awarded recommendation grade A or a “strong” 
recommendation, respectively.2 
 
As homeopathy is a topic of constant debate, both proponents and opponents frequently refer to the 
results from meta-analyses of the available clinical studies to support their respective stance in line 
with the highest scientific standards of EBM. With this in mind, an attempt will be made below to 
provide an outline of the most important global meta-analyses performed on clinical research into 
homeopathy. All relevant publications that are not limited to a single clinical indication are presented 
and discussed individually so as to formulate an overall opinion on this basis on the status of clinical 
research into homeopathy, insofar as this has been addressed by the given publications. The question 
that is relevant here is whether the clinical effects of homeopathy are placebo effects, or whether 
potentised medicines can produce specific effects. 
 
 
2.1. Kleijnen, Knipschild and ter Riet (1991)3 
 
This meta-analysis of homeopathy was published in 1991, namely during the era when EBM was in its 
infancy. The authors start by referring to what is often claimed: that homeopathy on the one hand is 
implausible, and on the other hand has not been investigated using modern methods (controlled 
studies). Kleijnen, Knipschild and ter Riet identified 105 evaluable studies that could be included in 
their analysis. Of these, 14 examined classical homeopathy involving the individual remedy selection, 
58 the prescription of a single homeopathic agent following clinical diagnosis (proven indication), 26 a 
combination of remedies, and 16 isopathy. The studies were evaluated for their quality using an 
independent method and awarded scores, with the results being included in the final analysis with 
different weightings based on their score. A total of 81 studies indicated efficacy for homeopathy in 
excess of placebo effects. Of these, the majority were rated as methodologically good in terms of 
randomisation, blinding, patient number and similar methodological criteria (15 out of 22). Overall, 
Kleijnen, Knipschild and ter Riet (1991) criticise the fact that many studies tend to be of low quality, 
whilst at the same time noting the trend in favour of homeopathy, both in those with a sophisticated 
design and those which, in their methodology, are rather weak. 
 
                                                 
1
 Cf. Cochrane (2014) 
2
  Cf. Harbour & Miller (2001) 
3
  Kleijnen, Knipschild and ter Riet (1991) 
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The authors conclude: “At the moment the evidence of clinical trials is positive but not sufficient to 
draw definitive conclusions because most trials are of low methodological quality and because of the 
unknown role of publication bias. This indicates that there is a legitimate case for further evaluation of 
homoeopathy, but only by means of well performed trials.”4 
 
 
2.2. Linde et al. (1997)5 
 
In the light of the question whether the clinical effectiveness of homeopathy can be explained solely by 
placebo effects, Linde et al. (1997) conducted a meta-analysis of all placebo-controlled, randomised 
and/or double-blind clinical trials of homeopathy published in the renowned journal The Lancet. Of the 
119 studies identified, 89 contained sufficient data to be included in the meta-analysis. Linde et al. 
evaluated this subset for its methodological quality using their own method of assessment, performed 
by two independent experts whose results were compared against one another. A high level of 
agreement was achieved in the assessment (interrater reliability: к=0.76). The average quality of the 
examined studies (n=89) with regard to randomisation, double-blinding, handling of study dropouts, 
etc., was 52% of the maximum value on a generally accepted scale for evaluating the quality of clinical 
trials (Jadad Scale). 
 
The analysis included 13 publications on individualised single-agent homeopathy (classical 
homeopathy), 49 that examined prescribing based on clinical diagnosis, 20 that used complex 
homeopathic remedies, and seven based on isopathy. Of the studies included, 22% examined 
moderate potencies (according to the definition by Linde et al. D9 – D23 or C5 – C11) and 37% high 
potencies (above D23 or C11, likewise as per Linde et al.), whereby both substance groups according 
to the authors theoretically contained too few molecules of the starting substance to exert any 
pharmacological activity (estimated total concentration per patient of less than 10-13 mol/L). 
 
The 89 studies included in the meta-analysis revealed that homeopathy was significantly superior to 
placebo (mean odds ratio 2.45; 95% confidence interval 2.05-2.93). In the case of the 26 studies rated 
as good methodologically, Linde et al. calculated lower, yet still significant efficacy versus placebo 
(odds ratio 1.66; 95% confidence interval 1.33-2.08). This result proved to be robust, moreover, in 
various sensitivity analyses (e.g. only the studies of the best quality with pre-defined endpoints which 
are listed in the MEDLINE database, n=5: odds ratio 1.97; 95% confidence interval 1.04-3.75). 
Correction of the results due to potential errors that could have arisen from selective reporting 
(publication bias) also did not eliminate the positive effects of homeopathy. Considering the initial 
question of their meta-analysis, the researchers ultimately concluded: 
 
“The results of our meta-analysis are not compatible with the hypothesis that the clinical effects of 
homoeopathy are completely due to placebo. However, we found insufficient evidence from these 
studies that homoeopathy is clearly efficacious for any single clinical condition. Further research on 
homoeopathy is war-ranted provided it is rigorous and systematic.” 
 
The criticism arising from this meta-analysis was aimed primarily at the quality of the studies included, 
which Linde et al. (1997) evaluated using their own system and included, accordingly, in their final 
analysis. In response to this, the authors screened the material again and created subsets depending 
on the Jadad score attained by the studies, at which point they introduced an external assessment 
scale.6 In this reanalysis it transpired that the superiority of homeopathy over placebo was lessened to 
                                                 
4
 Kleijnen, Knipschild and ter Riet (1991) 
5
 Linde et al. (1997) 
6
 Linde et al. (1999) 
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some extent if studies of higher quality were considered, without disappearing completely and without 
this correlation being linear: The ten studies with the highest Jadad score of 5 demonstrated that the 
effect of homeopathic treatment was greater than in the 19 studies with a Jadad score of 3 and the 11 
studies that achieved a score of 4. On the whole, it was found that homeopathy was significantly 
superior to placebo treatment in each of the six subsets created on the basis of the Jadad score. The 
argument that the higher the quality of the study design, the lower the effect of homeopathic treatment, 
was thus refuted. 
 
 
2.3. Cucherat et al. (2000)7 
 
This meta-analysis was undertaken as part of a report for the European Parliament. The authors 
conducted a systematic literature review and contacted pharmaceutical companies to identify 
randomised, placebo-controlled trials into homeopathy. Only those studies were considered in which 
potencies above C3 were used, or products designated by the manufacturer as “homeopathic”. A lack 
of blinding was not deemed to be an exclusion criterion. Only studies with a clearly defined primary 
endpoint were taken into consideration. Two experts were appointed to evaluate the quality of the 
studies. If their opinions differed, a third expert was consulted. Determination of the mean significance 
level (p-value) was used as the statistical method for meta-analysis, because the included trials were 
very heterogeneous as regards the treated diseases, prescribing methods and endpoints. A combined 
p-value of less than 0.05 signified in this case that the null hypothesis was incorrect and the 
homeopathic treatment thus differed significantly from placebo. 
 
Of the 118 studies identified, 16 were included in the meta-analysis. The others, in the opinion of the 
authors, either had no clearly defined endpoint (92.9%) or were methodologically deficient. One of 
these 16 studies contained a total of three groups (standard treatment, homeopathy and placebo). 
Hence, 17 comparisons of “homeopathy versus control” were analysed in total. Of these 17 study 
outcomes, 11 (65%) delivered a result in favour of homeopathy; three suggested superiority for 
placebo that was below the significance level. As the overall conclusion from analysing all the studies 
that fulfilled their inclusion and exclusion criteria, Cucherat et al. thus reported a highly significant 
mean p-value of 0.000036, which demonstrates clear efficacy for homeopathy versus placebo. The 
authors concluded that this outcome was not significantly influenced by publication bias, as by their 
estimation 155 notional trials with a negative or non-significant outcome would have been required to 
increase the composite p-value of their meta-analysis to above 0.05. A subset analysis revealed, 
however, that the significance level in an analysis of only those studies with a dropout rate of less than 
5% (n=5) was not achieved (p=0.082). Based on this conclusion, Cucherat et al. postulated: 
 
”There is some evidence that homeopathic treatments are more effective than placebo; however, the 
strength of this evidence is low because of the low methodological quality of the trials. Studies of high 
methodological quality were more likely to be negative than the lower quality studies.“8 
 
This cautious overall judgement is based on the definition of “methodological quality”, which in the 
given case is largely based on the rate of dropouts. Use of the same criterion as the main parameter 
for judging the quality of the study is questionable, however. What is essential to the reliability of the 
study outcome is not primarily the number of patients ending treatment prematurely, but rather the 
total number of cases, the correct randomisation of the subjects to the study groups, the blinding of 
patients and physicians, etc. In terms of the dropout rate the statistical method used to compensate for 
                                                 
7
 Cucherat et al. (2000) 
8
 Cucherat et al. (2000) 
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the resulting loss of data is mainly relevant to study quality. 9  To this end there are different 
approaches, some of which are suitable for rendering dropout rates of far more than 5% 
manageable.10 The corresponding methods are standard practice in epidemiology, and the criterion 
chosen by Cucherat et al. for evaluating the study quality in their meta-analysis, along with the 
limitation of the conclusion of their meta-analysis that resulted, is therefore very unusual from the 
viewpoint of methodology. 
 
 
2.4. Shang et al. (2005)11 
 
This meta-analysis, published in the renowned journal The Lancet, triggered the loudest media echo 
of all scientific papers on the subject of homeopathy. The article was accompanied in the Lancet by an 
editorial announcing “The end of homeopathy”12. 
 
Shang et al. (2005) referred more or less to the same pool of data as that at the time of publication by 
Linde et al. (1997); the final analysis included only eight out of the 110 studies initially reviewed, 
however. These eight studies were selected as the largest from a pool of 21 rated at first as 
demonstrating good methodology. The combined odds ratio of these homeopathic trials was 0.88 
(95% confidence interval 0.65-1.19). For comparison, the authors initially selected 110 studies from 
the field of conventional medicine from a Cochrane database, of which six were rated as high quality 
and included in the final analysis with a combined odds ratio of 0.58 (95% confidence interval 0.39-
0.85). Shang et al. concluded: 
 
“Biases are present in placebo-controlled trials of both homoeopathy and conventional medicine. 
When account was taken for these biases in the analysis, there was weak evidence for a specific 
effect of homoeopathic remedies, but strong evidence for specific effects of conventional interventions. 
This finding is compatible with the notion that the clinical effects of homoeopathy are placebo 
effects.“13 
 
This meta-analysis attracted criticism from various authors who pointed out a number of weaknesses: 
 
Fisher 14  complained about the lack of transparency in study selection insofar as the original 
publication by Shang et al. (2005) contained no details of which eight studies were ultimately 
analysed. Such a situation is a glaring deviation from the scientific standards used in meta-analyses, 
as specified in the QUORUM guideline.15 This guideline demands, amongst others, that all studies 
considered in a review – both those ultimately analysed and those excluded from final analysis – be 
presented in detail alongside the criteria for such a selection process so that the results of the meta-
analysis and the path taken to obtain them can be understood. Although such a procedure is self-
evident with any scientific publication, Fisher (2006) believes that close observance of such standards 
must be demanded, especially of reviews that contain far-reaching, definitive conclusions, such as the 
one by Shang et al. (2005). 
 
                                                 
9
  Cf. Sakpal (2010) 
10
 Cf. EMA (2010) 
11
 Shang et al. (2005) 
12
 The Lancet (2005) 
13
 Shang et al. (2005) 
14
 Fisher (2006) 
15
 Moher (1999) 
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Fisher also doubts the accuracy of the fit of the 110 studies in conventional medicine against those in 
homeopathy. The latter were, on average, of much higher quality, as a result of which the probability 
of a positive result diminishes. Shang et al. failed, moreover, to conduct sensitivity analyses which 
would have revealed the extent to which the negative outcome depends on study selection.16 Rutten 
and Stolper (2008) were of a similar opinion: 
 
“Re-analysis of Shang’s post-publication data did not support the conclusion that homeopathy is a 
placebo effect. The conclusion that homeopathy is and that conventional is not a placebo effect was 
not based on comparative analysis and not justified because of heterogeneity and lack of sensitivity 
analysis.“17 
 
Such a detailed sensitivity analysis was therefore produced by Lüdtke and Rutten (2008) once it 
became known which eight studies had led to the presented result. It was found that the analysis of 
the 21 high-quality studies from the pool collated by Shang et al. (2005) demonstrated significant 
superiority for homeopathy over placebo. The negative conclusion ultimately presented by the authors 
is influenced essentially by one single, large study that examines the efficacy of one homeopathic 
remedy in the prevention of muscle soreness.18 
 
Another weakness of the meta-analysis performed by Shang et al. is the heterogeneity of the very few 
selected studies in relation to the global statement derived from them as a result. The authors 
analysed a pool of studies that examined the efficacy of potentised medicines in the prevention of 
colds, treatment of warts, prevention of aching muscles, treatment of migraines, childhood diarrhoea, 
and severe brain injuries, jointly in only one study in each case. This is a method whereby 
consideration should be given to the possibility that homeopathy is an effective treatment for certain 
indications, but not for others. If one were to compare, as part of a meta-analysis, three clearly 
negative studies of conventional medicine in the treatment of cancer, soft-tissue injuries and rheumatic 
disease with specific drugs against a slightly positive study in the treatment of headaches with aspirin, 
its negative outcome would not likely be suitable for concluding that all conventional pharmacological 
interventions are generally ineffective. 
 
As the author of the first major meta-analysis of homeopathy, likewise published in the Lancet, Linde 
also agreed with many of the presented criticisms, as did other experts in the area of researching 
complementary medicine.19 On the whole, it must be concluded that there were clear methodological 
weaknesses in the review by Shang et al. and that their conclusion is based on a relatively small 
number of studies that were selected according to questionable criteria. 
 
 
2.5. Mathie et al. (2014) 
 
The most recent meta-analysis of homeopathy was performed by Mathie and colleagues in 2014. It 
included only those studies with a method of treatment that could be classified as “individualised 
homeopathy”. This approach is based on the authors’ assumption that prescribing potentised 
medicines cannot necessarily be interpreted as an adequate criterion for it to be associated with a 
single coherent treatment procedure. Clinical homeopathy, complex homeopathy, isopathy, etc., differ 
at least from the individualised approach of classical homeopathy in that the latter regularly involves 
                                                 
16
 Cf. Fisher (2006) 
17
 Rutten & Stolper (2008) 
18
 Vickers et al. (1998) 
19
 Cf. Linde and Jonas (2005), and Bell et al. (2005) 
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much longer diagnostic periods. This situation could explain a serious difference compared to the 
other prescribing practices. 
 
Mathie et al. thus take an initial step away from the concept of global meta-analysis, which attempts to 
answer the question whether any method that can be subsumed under the generic term of 
homeopathy is effective. This approach permits a more differentiated view of some of the available 
data than some previous reviews, even if Linde et al. (1997) already performed subset analyses which 
refer to different methods of prescribing potentised medicines. 
 
Yet the limitation to 32 studies that examine individualised homeopathy is not the only characteristic 
feature of the meta-analysis by Mathie et al. The review of the quality of the individual studies, by 
assessing the risk of bias using a tool of the Cochrane Collaboration 20 , is also new. Their 
methodological guidelines represent the state of the art of EBM, especially with regard to systematic 
reviews and meta-analysis. In their methodology, therefore, Mathie et al. are at the height of the game 
with their approach. 
 
Of the 32 included studies, 22 delivered sufficient data to warrant inclusion in the final analysis. These 
studies delivered a significantly positive result for homeopathy (OR 1.53; 95% confidence interval 
1.22-1.91). The assessment of the retrieved study material performed by Mathie et al. (2014) with 
respect to the seven aspects (domains) of methological quality (blinding, randomisation, selective 
reporting, etc.) according to the Cochrane criteria, however, meant that only three studies were graded 
as reliable. The combined odds ratio of these publications, at 1.98 (95% confidence interval 1.16-
3.38), was higher than the average, but given the exclusion of the majority of the retrieved material the 
database was so small that the authors stated: „Though our conclusions can be made most securely 
from three trials with reliable evidence, this sub-set of studies is too small to enable a decisive answer 
to our tested hypothesis.“21 
 
The main results of the meta-analysis by Mathie et al. confer, in their opinion, with those of previous, 
comparable reviews: Specific (minor) effects are identifiable with homeopathic treatment. These are 
robust, insofar as sensitivity analyses for different subsets of the analysed studies allow similar effect 
sizes to be identified. The quality of the evidence found was judged overall to be low or unclear. 
Hence, no definitive conclusions could be drawn. Consequently, more high-quality RCTs of 
individualised homeopathy are required in order to formulate reliable statements.22 
 
 
3. Conclusion 
 
In the light of the relevant global meta-analyses of homeopathy published to date it is clear, on the 
whole, that in four out of five cases potentised medicines tend to reveal specific efficacy in excess of 
placebo. The overall outcome is only negative (homeopathy = placebo) if a large amount (90%-95%)23 
of the available data is excluded from the analysis and/or dubious statistical methods are employed. In 
each of these cases measures are used that deviate from the usual scientific standards insofar as the 
desired increase in reliable data, by excluding studies with certain features, is not reasonably in 
proportion with the accepted narrowing of the database (for example, a dropout rate of <10% = 9 
studies versus <5% = 5 studies; see above).24 
                                                 
20
 Higgins & Altman (2011) 
21
 Mathie et al. (2014) 
22
 Ibid. 
23
 Cf. Hahn (2013) 
24
 Cf. Cucherat et al. (2000) 
39 
 
 
 
 
 
Behnke J. Meta-analyses in homeopathic clinical research. 2016. 
 
An exception here is the latest study by Mathie et al. (2014), which likewise judges a large proportion 
of the data found as (relatively) unreliable. In doing so, however, the authors refer to accepted 
standard procedures, and their study produces a positive result for homeopathy. The only study to 
ultimately conclude that the clinical effects of homeopathy can be explained entirely by placebo 
effects25 reveals considerable shortcomings in terms of methodology. 
 
In homoepathic research, the evaluation of data on the basis of (in)compatibility with certain 
theoretical preconceptions appears to play a significant role. As far as scientific theories are 
concerned, this phenomenon is referred to as plausibility bias.26 Hahn (2013), for instance, analysed 
the inclusion and exclusion criteria of studies in meta-analyses of homeopathy with a negative or 
indifferent tendency, revealing, on the basis of statistical considerations amongst others, that they 
were probably formulated retrospectively. He suspects that this methodological approach was 
ideologically motivated, which would diametrically oppose the scientific demands of EBM.27 
 
The authors of the reviewed publications, however, more or less agree that the available evidence 
does not permit any definitive conclusions to be drawn concerning the efficacy of potentised medicines 
in individual diseases – the reason being that independent replications of high-quality randomised, 
placebo-controlled, double-blind trials referring to one and the same indication are lacking. 
 
Along with other considerations, this observation points the way for the future of homeopathic 
research: In this respect an evaluation of the available data from the perspective of model validity 
would be useful, along with the design of new, harmonised studies that then results. This could be 
achieved with meta-analyses which, with greater differentiation than hitherto, consider individual 
prescribing methods and/or, in particular, indications for homeopathic treatment. New data could also 
lead to reviews that cover material not previously considered, including non-interventional studies for 
example, and on this basis offer a more comprehensive picture of the evidence available on 
homeopathy. 
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Status of basic research in homeopathy 
 
Stephan Baumgartner 
 
_________________________________________________________________________________ 
 
 
Homeopathy is based on three principles: testing the remedy in healthy individuals, the similarity 
principle, and potentisation. Basic research in homeopathy focuses on scientific evidence for the 
similarity principle, and potentisation as a pharmaceutical process. 
 
Criticism of homeopathy is aimed primarily at the process of potentisation, as from the perspective of 
natural sciences and pharmacology there are various arguments that question the meaningfulness of 
using potentisation as a pharmaceutical process. This includes, amongst others: 
• The content of active substances decreases exponentially, to a large extent, on potentisation. 
With simple anorganic compounds (such as calcium, sodium, silicium), lower dilutions, which 
in practice correspond roughly to 6x-9x, cannot be produced beyond the ubiquitarity limit 
(ppm-ppb depending on the material used). With plant and animal extracts it can be assumed 
that as of a potency level equivalent to the inverse of the Avogadro number in terms of its 
degree of dilution (approx. 24x), the probability of tracing just a single molecule of the starting 
substance in the potentised drug rapidly reaches zero. For this reason, questions are raised 
concerning specific effects from drugs diluted to higher potencies. 
• At lower potencies (to approx. 6x/9x), the substance content can deviate considerably from 
the nominally expected concentration – for instance due to minimal solubility in water (e.g. 
with metals), or due to adsorption at the vessel walls or dissolution from the same. From the 
viewpoint of natural science and pharmacology, this results in undefined concentrations in 
potentised drugs. 
 
 
Goals of basic homeopathic research 
 
In response to the specificity argument, preclinical research into potentised drugs in recent decades 
has primarily addressed the question of the existence of possible specific effects from higher-potency 
drugs in biological models. Given the difficulties reproducing results achieved (1), the latter question 
has developed in the last 20 years into one concerning the development of apt scientific methods: 
methods that as far as possible should satisfy the object of the study in its specific properties and 
effects – also with a view to obtaining reproducible results (2). Another question concerned 
establishment of a correlation between potency level and effect, i.e. determining the dose-effect 
relationship. Only few studies addressed the question of pharmaceutical optimisation (e.g. number of 
shakes on potentisation) or resistance of the potentised drugs to environmental influences. With a 
view to identifying the pharmaceutical mechanism of action, studies were also conducted to determine 
any specific physicochemical properties of potentised drugs. 
 
 
Models and methods of basic homeopathic research 
 
Scientific literature related to preclinical research into potentised drugs is comprehensively 
documented in the HomBRex database (3). In 2013, this database contained entries on 1,868 
experimental studies discussed in 1,383 publications (3). Four large preclinical research areas with 
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potentised drugs can be distinguished: (A) physicochemical measurements, (B) in vitro assays (cell 
cultures, microorganisms), (C) bioassays with plants and (D) animal experiments, the latter accounting 
for more than 50% of all studies (4). 
 
Research related to physicochemical studies into potentised drugs was last summarised in a review 
conducted in 2003 (5). The results from 36 studies were presented in 44 publications. The methods of 
analysis were divided into six categories: electrical impedance, electrochemistry, spectroscopy, 
nuclear magnetic resonance, Raman spectrosopcy and methods with unknown principles (black box 
methods). Half of the studies used nuclear magnetic resonance, where reproducible results were also 
achieved across various studies. Based on the currently available data, there are no empirical 
indications of stable water clusters in potentised drugs (6, 7), which have been hypothetically 
demanded as carriers of potential drug information (8). In several independent studies that measured 
NMR relaxation times (T1/T2), however, there were clear and consistent differences between 
potentised silicea products and relevant shaken controls which were interpreted as modified molecular 
dynamics in water (9). UV spectroscopy also revealed consistent differences between potentised 
substances and corresponding controls (10). A theoretical model that interprets such modifications as 
carriers of specific drug effects has not yet been devised, however (9). Since 2000, there has been a 
marked upswing in physicochemical research into potentised drugs. Hence, by the end of 2015 more 
than 150 publications had been identified as part of a systematic review, the content of which is 
currently being evaluated by an international study team. The research field is characterised by many 
different methods which in some cases are employed only in individual studies and often have not 
been replicated. Examples are the investigation for nanoparticles (11) or the reactivity of dyes (12). 
 
The study of potentised products by means of in vitro assays was last addressed in a review 
performed in 2007 (13). The 67 experimental studies that were evaluated can be divided into cell-free 
systems (e.g. enzymatic models), cell cultures, and models with cells from donated blood. Amongst 
the latter, those involving human basophils account for a considerable percentage (42%) of all the 
studies. The model used most frequently is inhibition of basophil degranulation by potentised 
histamine. Several replication studies and one multicentre study are available on this subject (14). It is 
noticeable from the studies with human basophils that effects could also be seen in various 
independent studies as a result of high potencies (beyond the inverse of the Avogadro number). The 
pattern of active and inactive potency levels within a given sequence of potencies (the “potency 
curve”) differed in each study (15), however – both between the different laboratories and on repeating 
the process at the same laboratory (16). As the basophils originated in each case from different blood 
donors, it is conceivable that the results depend on the individual donor. There is no empirical 
evidence of such to date, however. 
 
Plant bioassays are the third research field with respect to the effect and efficacy of potentised 
substances. The status of the research was last examined systematically in 2009/2011 (17-19). In the 
three main fields, i.e. bioassays with healthy plants, intoxication models and phytophathological 
studies, a total of 167 experimental studies were counted in 157 publications. Of these, 48 fulfilled 
higher standards of quality and were analysed more closely (20). The test organism used most 
frequently was wheat, followed by duckweed and peas. The most commonly used stressor was 
arsenic. Silver nitrate was most often used as the potentised substance, followed by arsenic and 
gibberellic acid. In various studies, specific effects – also of potencies beyond the inverse of the 
Avogadro number – were observed. In the models that examined continuous series of potencies, a 
discontinuous relationship between effect and potency level was observed in all cases, i.e. effective 
and ineffective potencies alternated according to a defined, albeit different sequence depending on the 
study. 
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With respect to the fourth large research field, namely animal experiments, only reviews that offer a 
cursory description or are limited in terms of time or subject matter have been found recently – 
probably on account of the large number of scientific studies overall (4). The studies were in most 
cases performed on rats (35%) or mice (29%) (4). The employed research concepts were categorised 
by way of example using the rat (21). In most of the experiments a specific disease was artificially 
induced in the animals. In the majority of cases this entailed intoxication (e.g. with arsenic, lead, CCl4), 
induction of behavioural disorders (e.g. with ethanol, caffeine), inflammatory models (e.g. with 
carrageenan) or induced hormonal disorders. The animals were then treated either prophylactically or 
curatively with potentised medicines (before or after induction of the disease, respectively). A 
systematic review of 105 publications is available on the studies in experimental toxicology (22). A 
total of 26 studies were included in a quantitative meta-analysis. A mean protective index of 19.7% 
resulted for the examined indications (survival rate, excretion of toxins) after administering potentised 
substances, which were selected according to the isopathic principle. Aside from artificially induced 
disease models, there were two other model clusters in which the effect of potentised substances was 
investigated: development models and animal behaviour models. In case of the development models, 
studies repeatedly involved an amphibian model in which the effect of thyroxine 30x on the 
metamorphosis of Rana temporaria was examined. The inhibitory effect of thyroxine 30x on such 
metamorphosis was judged to be significant in a meta-analysis of 26 studies. The effect appears to be 
quite robust, moreover, as both internal and external reproducibility was rated as positive (23). A more 
recent review of animal behaviour models identified 18 publications that spanned a wide range of 
models and methods (24). There was an emphasis on the potentised drugs Ignatia, Gelsemium and 
Chamomilla. Potentised Gelsemium products, used in a number of studies, exhibited highly significant 
effects in behavioural experiments on mice which were of the same magnitude as conventional 
psychopharmaceuticals at substantial dosage (24). 
 
In summary it can be stated that preclinical research into potentised drugs is characterised by a wide 
variety of methods and tested drug potencies. The large number of scientific publications also includes 
many studies of good quality that deliver empirical evidence of specific effects for potentised drugs, 
also for highly diluted potentised products. 
 
 
Research into the dose-effect relationship 
 
The outcome of preclinical research into potentised products that has been most adequately 
confirmed empirically is the phenomenon of the non-linear relationship between the effect and potency 
level. To my knowledge, in every preclinical study that investigated several potency levels of the same 
substance, effective and ineffective potency levels were reported to appear consecutively according to 
a particular pattern (referred to, after Kolisko (25), as the “potency curve”) (17-19, 24). These patterns 
generally prove to be stable within one series of tests (26-28), but over time can also change (28) or 
differ between independent laboratories (14, 16). To date, no potency curve has been identified that 
remained stable either for the tested potentised substance, the experimental method, or a combination 
of substance and method. It is not possible to say at the moment whether this is due to as yet 
unidentified determinants or to a particular phenomenon that is inherent to the effects of potentised 
drugs. 
 
 
Research into the similarity principle 
 
The principle of similarity has been investigated far less intensively than that of potentisation: the 
current status of research was last reviewed in 2011 (29). Research into hormesis clearly 
demonstrated that low doses of a stressor administered before or after an acutely toxic, higher dose of 
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the same stressor can ameliorate these harmful effects – both clinically and preclinically (29). Within 
the context of homeopathy, this may be regarded as empirical evidence of the isopathic principle. The 
best empirical evidence for applicability of the similarity principle (treating “like with like”) in the field of 
preclinical research has been obtained by a Dutch study team with studies into cell cultures. The cells 
in these studies were firstly exposed to a heat shock. Subsequent treatment with low doses of a series 
of different stressors revealed that the survival rate was better, the more similar the respective stressor 
was to the heat shock in terms of the spectrum of proteins that developed (30). 
 
 
Research into the biological mechanism of action 
 
Difficulties reproducing the results from research into potentised substances could be caused by the 
fact that the experimental systems and/or parameters chosen to document the nature of the effect of 
potentised substances are inadequate. For example, it has been postulated that the activity of 
potentised substances is not aimed primarily at exerting a particular effect in a particular direction 
(irrespective of the system and its condition), but rather at having compensatory effects or promoting 
homeostasis. Translated into an experimental language, this means that primarily effects are not to be 
anticipated as regards the mean value of a population, which is reproducibly shifted in a certain 
direction, but that the scattering of the system is reduced. This is what was observed in a meta-
analysis across various experimental systems in which the activity of potentised arsenic was 
investigated (31). Whether this phenomenon should be attributed specifically to the effect of 
potentised arsenic, or whether it is characteristic in general to the effect of potentised drugs, cannot be 
determined at present due to the lack of experimental data. 
 
There are some indications that the status of an experimental system decisively influences the 
response to a treatment with potentised substances. The response of Pisum sativum to treatment with 
potentised gibberellic acid depends on the batch of seed, for instance (32). The metamorphosis of 
Rana temporaria is only influenced by potentised thyroxine if the amphibians originate from highland 
habitats (33, 34). Lemna gibba responds to potentised gibberellic acid only if the organisms are in a 
gibbous state (28). The therapeutic effect exerted by potentised Lyopodium in the phytopathological 
model system Malus domestica / Dysaphis plantaginea is especially pronounced if the stress from D. 
plantaginea is not too high (35). These examples clearly indicate that potentised substances are seen 
to exert an effect in particular if the test organisms are in a mildly, yet not excessively, stressed state. 
The degree of divergence from homeostasis evidently may only be so great that the organisms can 
regain a state of equilibrium on their own. This statement is to be taken as a working hypothesis at 
present and should be carefully examined in the process of developing further methods. After 
verification, it could be rated as evidence for a part of the biological mechanism of action of potentised 
drugs. 
 
Another aspect of the mechanism of action is formulated in the hypothesis that potentised drugs exert 
their effect at the level of the ability of the whole organisms to regulate itself. Empirical evidence is 
available in this regard from a number of experimental oncology studies in animals. By systematically 
administering potentised drugs in the animals inoculated with cancer cells, the number and size of the 
developing tumours were decreased; treatment of the cancer cell lines with the same potentised drugs 
in vitro revealed no activity whatsoever (36-39). These results speak clearly in favour of an effect at 
the higher level of the organism as a whole. This aspect of the biological mechanism of action of 
potentised drugs must also be determined more precisely in future studies. The relevance to the 
design of preclinical models is evident: If the hypothesis fits, any efficacy in potentised drugs cannot 
be expected from studies in cancer cell lines (40). 
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Reproducibility of basic homeopathic research 
 
In 2010, a systematic review to address the question of the reproducibility of effects in basic research 
of potentised products identified 24 experimental models that had been used in a total of 107 studies 
and were repeated internally at the laboratory or externally (41). Repeat studies in 24 of these models 
revealed similar results in 22, differing results in 6, and no effects in 15 models. Independent 
reproductions delivered significant results with 7 models. It can therefore be stated that preclinical 
research into potentised drugs in the last 10 years has made clear progress: in 1999, no single 
experimental model was known in which the results could be reproduced independently (1). 
 
 
Outlook 
 
Given the advances in methodology, the prospect of addressing diverse questions of scientific and 
pharmaceutical relevance is becoming more realistic. Consideration must first be given to determining 
the mechanism of action of potentised drugs, at both the pharmaceutical and biomedical level. From 
the pharmaceutical perspective, two concepts are conceivable: (1) consolidation and methodological 
expansion of the physicochemical studies for determining the specific molecular structure and 
dynamics of potentised drugs, and (2) physical interventions into potentised drugs, the effects of which 
can be investigated with appropriate bioassays and which then permit conclusions to be drawn on the 
mechanism of action. Furthermore, established test methods could be used to examine 
pharmaceutically relevant issues, especially with respect to stability under external influences (heat, 
pressure, sterile filtration, electromagnetic radiation, etc.) and also with regard to stability in general. 
 
 
Working groups and organisations 
 
In Europe there are five working groups at present that focus closely on questions of basic research 
into potentised products. These working groups are based at the University of Witten/Herdecke 
(Germany, Dr Stephan Baumgartner), the University of Bern (Switzerland, Prof. Ursula Wolf), the 
Interuniversity College of Graz (Austria, Prof. Christian Endler), the University of Verona (Italy, Prof. 
Paolo Bellavite) and the University of Bologna (Italy, Prof. Lucietta Betti). Elsewhere, there are several 
university-based working groups in Brazil and India. 
 
Notable organisations are the GIRI (Groupe International de Recherche sur l'Infinitésimal, 
www.giriweb.com), a scientific association dedicated to basic research into potentised products, the 
Karl and Veronica Carstens Foundation as the supporters of the HomBRex database (www.carstens-
stiftung.de), and the HRI (Homeopathy Research Institute), as the organiser of conferences on the 
subject of homeopathic research (www.homeoinst.org). 
 
 
Summary 
 
The following can be concluded on the status of preclinical research into potentised substances: 
Amongst the available specialist scientific publications, totalling more than 1,000, there is a significant 
collection of studies of high quality that has delivered empirical evidence of specific efficacy, also with 
highly diluted, potentised drugs. Likewise, there are several experimental models with which 
significant specific effects were observed for potentised products when replicated independently. The 
empirically ascertained modification of molecular dynamics in potentised drugs could give indications 
of the physicochemical and pharmaceutical mechanisms of action, which as a whole must still be 
determined, however. There is also initial empirical evidence of the biological mechanism of action, 
described by a regulatory reaction of the entire organism to deviations from homeostasis. 
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